← Eichor
Study identifier: NCT06180993 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization

Condition: RSV Infection  ·  Sponsor: Federico Martinón Torres

PhaseN/A
Planned participants42000
Who can joinAll sexes, 1 Day to 24 Months
Healthy volunteersNo

About this study

A longitudinal observational study based on routinely collected data on hospital and health care use for RSV infections will be undertaken. The Galician public health registries will be used for data collection including baseline information and follow-up data. Historical data will be retrieved for comparison purposes. The study aims to observe and analyze data from all the eligible children in Galicia for nirsevimab treatment. The number of eligible children is expected to be approximately 14,000 per each RSV season.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital Clínico Universitario de Santiago de CompostelaSantiago de Compostela, A Coruña, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06180993